How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Glucose Therapy System Market
- By Product Type: Continuous Glucose Monitoring Systems (CGM), Self-Monitoring Blood Glucose Devices (SMBG), Insulin Pumps, Integrated Insulin Delivery Systems, Non-invasive Glucose Monitoring Devices
- By End User: Hospitals, Clinics, Home Care Settings, Diagnostic Laboratories, Ambulatory Surgical Centers
- By Technology: Electrochemical Sensors, Optical Sensors, Enzymatic Sensors, Microfluidic Sensors, Non-invasive Spectroscopy
- By Application: Diabetes Management, Hypoglycemia Monitoring, Hyperglycemia Monitoring, Gestational Diabetes Monitoring, Research and Clinical Trials
- By Component: Glucose Sensors, Insulin Delivery Devices, Data Management Software, Calibration Solutions, Wearable Devices
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Continuous Glucose Monitoring Systems (CGM) leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 307 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Blood Glucose Therapy System Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
End User 5
Technology 5
Application 5
Component 5
Companies profiled
Abbott Laboratories
Dexcom Inc.
Medtronic plc
Roche Diabetes Care
Ascensia Diabetes Care (a Panasonic Healthcare company)
LifeScan
Inc. (a Johnson & Johnson company)
Sanofi
Bayer AG
Insulet Corporation
Tandem Diabetes Care
Nipro Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Dexcom Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Roche Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Ascensia Diabetes Care (a Panasonic Healthcare company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →LifeScan
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (a Johnson & Johnson company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bayer AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Insulet Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Tandem Diabetes Care
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Terumo Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Arkray Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →A. Menarini Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →GlucoMe
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$6,304M by 2033 · 4.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Continuous Glucose Monitoring Systems (CGM)46.2
- Self-Monitoring Blood Glucose Devices (SMBG)17.4
- Insulin Pumps9.0
- Integrated Insulin Delivery Systems17.4
- Non-invasive Glucose Monitoring Devices10.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,443M → $2,335M · 6.2%
Europe$1,006M → $1,498M · 5.1%
Asia Pacific$918.4M → $1,327M · 4.7%
Latin America$568.6M → $770.4M · 3.9%
Middle East and Africa$437.4M → $698.6M · 6.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.632026
4.652027
4.662028
4.662029
4.672030
4.692031
4.692032
4.712033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories15.5
- Dexcom Inc.22.2
- Medtronic plc7.1
- Roche Diabetes Care12.7
- Ascensia Diabetes Care (a Panasonic Healthcare company)5.1
- LifeScan9.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type18.4%
End User12.7%
Technology20.0%
Application24.7%
Component24.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.2
- Europe22.6
- Asia Pacific20.0
- Latin America11.6
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 89 | 96 | 78 | 86 | 87 | 96 | 89 |
| Dexcom Inc. | 73 | 80 | 79 | 72 | 80 | 79 | 77 |
| Medtronic plc | 68 | 66 | 73 | 86 | 64 | 67 | 71 |
| Roche Diabetes Care | 63 | 69 | 70 | 77 | 63 | 59 | 67 |
| Ascensia Diabetes Care (a Panasonic Healthcare company) | 71 | 53 | 61 | 67 | 70 | 57 | 63 |
| LifeScan | 56 | 69 | 51 | 51 | 48 | 55 | 55 |
| Inc. (a Johnson & Johnson company) | 49 | 57 | 62 | 46 | 49 | 40 | 51 |
| Sanofi | 44 | 44 | 54 | 36 | 44 | 44 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Dexcom Inc.
- Medtronic plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Dexcom Inc. | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Medtronic plc | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Roche Diabetes Care | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Ascensia Diabetes Care (a Panasonic Healthcare company) | ◐ | − | − | ◐ | − | ◐ |
| LifeScan | − | ✓ | − | − | − | − |
| Inc. (a Johnson & Johnson company) | − | ◐ | ◐ | − | − | − |
| Sanofi | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories89
2Dexcom Inc.77
3Medtronic plc71
4Roche Diabetes Care67
5Ascensia Diabetes Care (a Panasonic Healthcare company)63
6LifeScan55
7Inc. (a Johnson & Johnson company)51
8Sanofi44
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Abbott Laboratories
Challenger3
Strong scale, closing on the leaders.
Dexcom Inc.Medtronic plcRoche Diabetes Care
Contender1
Focused players with pockets of strength.
Ascensia Diabetes Care (a Panasonic Healthcare company)
Niche3
Specialists in a single segment or region.
LifeScanInc. (a Johnson & Johnson company)Sanofi
Go-to-market strategy
Land Product Type in North America, then scale across Blood Glucose Therapy System Market — a $492M beachhead inside a $7.50B market.
Beachhead (SOM)$492Mobtainable near-term
Serviceable (SAM)$2.93Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Continuous Glucose Monitoring Systems (CGM)
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Self-Monitoring Blood Glucose Devices (SMBG)
Strong fit — clear ROI and a fast path to value.
End user70 fit
Insulin Pumps
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Glucose Therapy System Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified26%
Evaluation13%
Closed-won7%
$13.6KCAC
$68KLTV
5.0:1LTV : CAC
< 3 moCAC payback
Investment thesis
Blood Glucose Therapy System Market is a durable-growth opportunity — $1.29B by 2033, compounding at 9.8%.
TAM · 2025$610Mtoday
TAM · 2033$1.29Bforecast
CAGR9.8%2027–2033
Cumulative$8.21Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.29BTotal addressable market
SAM$522MServiceable available market
SOM$99MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.8% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.29BLarge & growingTAM by 2033 at 9.8% CAGR
$522MServiceable nowreachable with today’s model
$99MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.00BBear6.4% CAGR
$1.29BBase9.8% CAGR
$1.65BBull12.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Glucose Therapy System Market — a $1.52B market by 2033. Plan: grow share from 8.3% to 14.0%.
Market size · 2033$1.52Btotal addressable
Market CAGR5.7%2027–2033
Target share14.0%from 8.3% today
Revenue ambition$213Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 14.0% | Behind |
| Revenue | $138M | $213M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.6% | 43.5% | Ahead |
| Customer retention | 84.9% | 93.5% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $24M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Sales deck · value proposition
Win the Blood Glucose Therapy System Market conversation — a $6.22B market you can size, segment and defend in minutes.
Market size · 2033$6.22Btotal opportunity
Growth8.0%CAGR to 2033
Addressable buyers1,655+accounts in scope
Typical ROI7.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.6×return on cost, year one
< 3 mopayback period
$58K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Abbott LaboratoriesDexcom Inc.Medtronic plcRoche Diabetes CareAscensia Diabetes Care (a Panasonic Healthcare company)LifeScanInc. (a Johnson & Johnson company)Sanofi+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Glucose Therapy System Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Glucose Therapy System Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Lancets Market
Market size, share, segmentation and regional forecast.
$514M market · 2025 base year
View reportBlood Lipid Meter Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBlood Management Labels Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportBlood Meal for Poultry Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBlood Meal, Meat and Bone Meal (MBM) Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportBlood Monitoring & Cardiac Monitoring Devices Market
Market size, share, segmentation and regional forecast.
$842M market · 2025 base year
View reportBlood Monitoring Device Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportBlood Orange Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportBlood Oxygen Measurement Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBlood Plasma Fibrinogen Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportBlood Plasma Freezer Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBlood Platelet Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.